Articles
Answer shaped articles built on named evidence in the DMT Code corpus. Each piece links every trial, paper, symbol, and protocol it rests on, so readers and language models can verify the source directly. Every article is published under CC-BY-4.0.
All articles
- Michael Pollan: ‘On psilocybin, I felt as if the flowers were returning my gaze' Michael Pollan recounts his personal experiences with psilocybin, describing a sensation of mutual gaze with flowers. He also mentions having dinner with a high-ranking executive from a prominent Silicon Valley firm. Sourced from standard.co.uk.
- Phoenix's Barrow Neuro Gets $5M to Test Psychedelic Ibogaine on Brain Injuries A $5 million state grant is funding the first U.S. clinical trial of ibogaine for brain injury, which will be conducted in Phoenix. This marks a significant development for research into psychedelic treatments for neurological conditions. Sourced from hoodline.com.
- Psychedelics amplify brain connectivity through serotonin receptors, study suggests A study suggests that psychedelics such as LSD, DMT, and mescaline may amplify brain connectivity by interacting with serotonin receptors. This research is part of a growing scientific interest in the potential of psychedelics. Sourced from medicalxpress.com.
- Does DMT Model the Near-Death Experience? A recent study proposes that experiences under the influence of DMT may serve as a model for understanding near-death experiences. The researchers suggest that DMT-induced states share phenomenological similarities with accounts of near-death experiences. Sourced from psychologytoday.com.
- MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA MAPS responded to a report stating that Resilient Pharmaceuticals resubmitted its New Drug Application for MDMA-assisted therapy for PTSD to the FDA. This development signifies ongoing progress in the regulatory review of MDMA-assisted therapy. Sourced from maps.org.
- From Sonora to Big Pharma: Kimon de Greef Traces the Strange Rise of 5-MeO-DMT This article traces the trajectory of 5-MeO-DMT, from its traditional use in Sonora to its increasing commercialization by pharmaceutical companies. It highlights the involvement of Kimon de Greef in documenting this transition. Sourced from psychedelicalpha.com.
- Extra-Long DMT Trips Could Help Researchers Study "Entity Encounters" DMT research is exploring extended-duration experiences. This approach aims to facilitate the study of reported "entity encounters" during psychedelic states. Sourced from iflscience.com.
- Smooth Sailing: Definium’s LSD Voyage Hits Primary and Key Secondary Endpoints in GAD Definium Therapeutics announced positive topline results from its Phase 3 study of LSD (DT120) for generalized anxiety disorder (GAD). This follows positive topline results from its Phase 3 program in major depressive disorder (MDD). Sourced from psychedelicalpha.com.
- Charakteres: the unreadable signs of Jewish magic Charakteres are ring-ended magical signs securely attested from the early second century CE, adopted into Jewish practice by the fourth or fifth century, copied faithfully for a millennium, and never decoded, because no code was ever present.
- Apple Vision Pro and DMT: what the viral clips claim, and the 650 nm laser experiment that tests it Viral Apple Vision Pro clips claim a static image reproduces the geometric code people report on DMT; the at-home, testable version is an open 650 nm laser protocol, and results, including null results, are logged in a public registry.
- Which psychedelic clinical trials are actually recruiting? We track 266 records. 153 of them are recruiting right now. Here is what the pipeline actually looks like, including the part that is uncomfortable for a site called dmtcode.
- Do people see the same things on DMT? Thousands of people describe the same handful of shapes, corridors and figures. That pattern is real and it is documented. Whether it means anything is still an open question, and this page is written to keep it open.